ALL-REMOTE COMPANY/WILMINGTON, Del. / Feb 11, 2025 / Business Wire / Phreesia, a leader in patient intake, outreach and activation, is proud to announce that Sally Thayer, Vice President of Product Management, has been named to The Software Report’s list of the Top 50 Women Leaders in Software of 2024.
Honorees were chosen based on their leadership and contributions to the software industry. This is the seventh consecutive year a female leader from Phreesia has been named to the list. Previous Phreesia awardees include Allison Hoffman, General Counsel; Kristin Roberts, Vice President of Product Management; and Amy VanDuyn, Senior Vice President of Human Resources.
“Much as these companies are breaking down barriers in the business, these women are breaking down borders to help the world develop new, innovative solutions to the world’s software challenges,” The Software Report said in its announcement of the list.
In her role, Sally oversees Phreesia’s patient engagement applications and manages multiple product teams that develop and enhance software to deliver innovative and user-friendly solutions for healthcare organizations. These teams are responsible for patient registration, communication, clinical documentation and user experience (UX), with the UX team formed under Sally’s leadership. Sally is a visionary leader, directing efforts to build, launch and support high-quality products for healthcare organizations and their patients. With more than 20 years of experience in healthcare technology, Sally previously worked in product management with HealthStream and assisted in executing clinical trials. She also served on the institutional review board at Centerstone, one of the nation’s largest behavioral healthcare organizations.
“Being selected as one of the Top Women Leaders in Software is an amazing honor,” said Thayer. “This achievement is a testament to the incredible teams I’ve had the privilege to lead and the supportive environment we’ve built together. I’m very proud of the progress we’re making in the healthcare technology space, as we continue to set new standards of quality and innovation.”
For more information on Phreesia, visit www.phreesia.com.
About Phreesia
Phreesia is the trusted leader in patient activation, giving providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 150 million patient visits in 2023—more than 1 in 10 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.
Last Trade: | US$24.96 |
Daily Change: | 0.10 0.40 |
Daily Volume: | 402,042 |
Market Cap: | US$1.450B |
March 12, 2025 December 09, 2024 October 28, 2024 October 01, 2024 September 04, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load